Aachen, Germany, 4 June 2022 – Hemovent GmbH (“Hemovent™”) has successfully showcased its product portfolio for the first time under its new MicroPort® flag at the 10th EuroELSO Congress in London, UK.
The EuroELSO scientific committee had developed an extensive program covering all aspects of extracorporeal life support therapies for the first in-person meeting for two years. Intensivists, cardiologists, cardiac surgeons, pediatric and neonatology specialists, perfusionists, intensive care units (ICU) nurses, physiotherapists, and dieticians gathered to share their clinical experience and discuss new technologies and latest directions in research.
Hemovent™ took the opportunity to present its unique extracorporeal life support (ECLS) MOBYBOX® system, which is the first extracorporeal membrane oxygenation (ECMO) device to integrate both blood flow control and gas management into a single device. “We are extremely proud to now be a part of MicroPort® and to build on the profound resources, industry expertise, and global reach to raise our unique technology to the next level. We are looking forward to scaling our commercial activities, ramping up operations, and extending our product portfolio as a MicroPort® innovation lab”, said Christof Lenz, CEO of Hemovent™.
With no reliance on an external power supply, software, or motors, the MOBYBOX® is driven only by pneumatics (oxygen or compressed air). Weighing less than 2 kg and able to fit in a backpack, MOBYBOX® has set a new standard for ECMO devices in terms of mobility and ease of use. The MOBYBOX® system is designed to extend device application from ICUs to mobile medical scenarios like patient transfer within and between hospitals, and field rescue. The MOBYBOX® is able to provide timely extracorporeal life support to a much higher number of critical patients in life-threatening situations, thus gaining valuable time for emergency treatment. Moreover, the fully integrated gas and pump management of the MOBYBOX® system is extremely easy to use and affordable, providing a much better solution for many primary hospitals in meeting their real-world care demands.
The global ECMO market exceeded USD 500 million in 2020 and is anticipated to grow at a compound annual growth rate (CAGR) of over low double-digit percentage between 2021 and 2027. The sudden surge in COVID-19 cases coupled with rising number of critically ill patients requiring extra life support has escalated the demand for ECMO devices. It is estimated that on top of the significant international market growth the market potential for ECMO in China surpasses 100,000 cases per year based on the usual usage of ECMO per million population.
Hemovent GmbH, based in Aachen, Germany (Hemovent™), a subsidiary and Innovation Lab of MicroPort Scientific Corporation (MicroPort®, stock code: 00853.HK), is a developer and manufacturer of highly innovative ECLS and ECMO products. Its flagship product, the MOBYBOX™ System, is the world’s first fully integrated and self-contained ECLS system for the treatment of cardiac and/or respiratory failure. It is extremely easy to use and surpasses all existing technologies in terms of size and transportability. Hemovent™ is committed to deliver best-in-class medical devices to save patients’ lives in severe cardiac or respiratory failure, which affects about 12 million people worldwide every year.